



Happy Fourth of July, and a great weekend ahead.

To our RxAir360 family, thank you for another month of trust and support. There is a lot happening right now, so this update runs a little longer than usual. We wanted you to have the full picture.

REGULATORY & PUBLIC MARKETS

A Detailed First Response to FINRA

After our initial Form 211 submission, FINRA came back with their first round of questions. That is a normal, expected part of this process. Very few applications move through without at least a few rounds of back and forth. Working closely with our securities counsel and our market maker, we prepared a thorough, detailed response addressing every point they raised. That response has now been submitted, and we are waiting to hear on next steps.

REGULATORY & PUBLIC MARKETS

A Note on Ticker Timing

A quick note on share conversion timing: no conversions will take place prior to ticker symbol assignment. That means everything on this front will happen after FINRA clears us and our ticker is assigned, while we prepare our company profile and website for OTC Markets. No action is required from shareholders at this time. We genuinely appreciate the volume of response and thoughtful feedback so many of you shared with us on this topic. It means a lot, and we will keep you posted as this moves forward.

PRODUCT & FDA PATHWAY

Eurofins Moves to Report Writing

As you know, our testing with Eurofins is complete, and the chamber passed. Eurofins is now focused on report writing, translating that testing data into the formal documentation the FDA requires. Starting Monday, July 6th, they will be dedicating their attention to RxAir360 exclusively, with no other project allowed to come in front of ours on their bench. We have also brought on an additional consultant to help make sure that documentation is structured exactly the way Eurofins and, ultimately, the FDA expect to see it. We believe this will help our submission move more smoothly when we file later this month.

ON THE ROAD

Venture Summit West

Since our last update, I had the opportunity to stand on stage and give a six-minute presentation on RxAir360 to a room of innovators, founders, and investors at Venture Summit West in Silicon Valley. Board Member Ashley Thaw joined as well, lending her healthcare operations experience to the conversations happening around the event, and Chief Sales Officer Tony Brown worked the room, networking throughout. It was a meaningful opportunity to build new relationships in one of the most active investment ecosystems in the country.

BRAND & MEDIA

In the Press

RxAir360 continues to gain visibility. We were recently featured in **International Business Times** and **Wellness Voice**, and following our IBTimes interview, their editorial team invited me to write an op-ed for their publication sharing an industry perspective on access to care. We will share that piece with you as soon as it is published, along with anything else that comes out of these conversations.

TEAM

Celebrating Our Own

We also took a moment to celebrate one of our own. Our Director of Investor Relations, Heather Isham, rang in her 65th birthday, and part of the team joined her in Halifax, Nova Scotia, Canada to mark the occasion. While we were there, we spent the weekend with our Canadian investors as well, including joining them for church. Tony Brown closed out the weekend by giving them an updated look at the RxAir360 pitch, and Jack Lessel, a Wealth Advisor at Wood Gundy Wealth Management, was there to answer investor questions directly. Moments like these are part of what makes this company feel like family, not just a business.

COMING UP

Invest Fest, Atlanta — August 7–9

Next month, we will have a booth at Invest Fest in Atlanta, at the Georgia World Congress Center. The event is expected to draw more than 50,000 attendees over three days, with a headline lineup that has included names like Steve Harvey, Serena Williams, T.I., and Nick Cannon. It is one of the largest financial empowerment events in the country, and a meaningful opportunity to put RxAir360 in front of a large, engaged audience.

FOUNDER'S NOTE

Locked Out of Healing

I am in the final stages of finalizing the manuscript for my book, *Locked Out of Healing: Why Patients Are Denied Care That Could Change Their Lives*. Once the manuscript is finalized, publishing takes about 30 days. From there, we are planning a media and press tour to build brand awareness and trust in RxAir360 ahead of bringing the device to market and beginning conversations with physician offices.

STAY CONNECTED

Follow Along

Between newsletters, the best place to catch public updates is our social media and website. If you want a deeper dive on the science, our website's blog now includes a 10-part educational series answering the most common questions about hyperbaric oxygen therapy. And for anything major, you will always hear it from us first, before it goes out anywhere else.

The full vision behind RxAir360 is coming to life, piece by piece. Every step we are taking right now, the FINRA process, the testing, the press, the book, Invest Fest, is about positioning this company to become what you believed in when you invested your hard earned money, shared our story with friends and family, and continued standing with us even when the process took longer than any of us expected.

We have asked a lot of you throughout this process: documentation, patience, and trust, and we do not take that for granted. Thank you for turning around what we have needed, quickly and without complaint, and for standing with us as we get closer to the finish line.

Diallo M. Watts, Sr.

Founder & CEO, RxAir360 Inc.

This update contains forward-looking statements, including statements regarding anticipated regulatory review timelines and outcomes, testing schedules, ticker assignment and share conversion timing, event participation, media coverage, and publishing timelines. These statements reflect current expectations and are subject to change. There is no guarantee of FINRA clearance, FDA clearance, ticker assignment on any particular timeline, or any other outcome described in this update, and actual results may differ materially.

RXAIR360 INC.